PTC Therapeutics appoints Matthew Klein as CEO; founder Stuart Peltz retires

PTC THERAPEUTICS, INC.

Stuart Peltz retires after 25 years as CEO; Matthew Klein appointed CEO and President, effective March 22, 2023.
Peltz will serve as Senior Advisor & join Scientific Advisory Board; consulting fee of $600k for first 12 months, then $400k.
Klein had been COO since Jan 2022; previously Global Head of Gene & Mitochondrial Therapies and Chief Development Officer.
Peltz receives prorated 2023 annual bonus equal to 25% of his 2022 bonus; unvested equity continues vesting during consulting period.
PTC's broad pipeline includes five registration-directed trials; Klein led EMA approval of Upstaza gene therapy.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Stuart W. Peltz

Chief Executive Officer

PTCT · PTC THERAPEUTICS, INC.

Effective: 2023-03-22
Successor: Matthew B. Klein
Filed: March 24, 2023, 7:59 PM ET

Dr. Stuart W. Peltz, who provided the Board with notice on March 22, 2023 of his decision to retire as Chief Executive Officer and as a member of the Board, in each case, effective as of March 22, 2023.

Appointed

Matthew B. Klein

Chief Executive Officer and President

PTCT · PTC THERAPEUTICS, INC.

Effective: 2023-03-22
Filed: March 24, 2023, 7:59 PM ET

the Board of Directors (the “Board”) of PTC Therapeutics, Inc. (the “Company”) appointed Dr. Matthew B. Klein, age 51, as Chief Executive Officer and President and a member of the Board, effective as of March 22, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Stuart W. Peltz retired as Chief Executive Officer at PTC THERAPEUTICS, INC..

Action: retired
Role: Chief Executive Officer

Exact text from the filing

Dr. Stuart W. Peltz, who provided the Board with notice on March 22, 2023 of his decision to retire as Chief Executive Officer and as a member of the Board, in each case, effective as of March 22, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Matthew B. Klein was appointed as Chief Executive Officer and President at PTC THERAPEUTICS, INC..

Action: appointed
Role: Chief Executive Officer and President

Exact text from the filing

the Board of Directors (the “Board”) of PTC Therapeutics, Inc. (the “Company”) appointed Dr. Matthew B. Klein, age 51, as Chief Executive Officer and President and a member of the Board, effective as of March 22, 2023.

View on SEC.gov

PTC THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-036263

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.